We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Melanocyte Stem Cells and UVB Responsible for Some Cancers

By LabMedica International staff writers
Posted on 01 Nov 2017
Cancer researchers working with mouse melanoma models have identified a mechanism responsible for the initiation of skin cancer through the interaction of ultraviolet light (UVB) and melanocyte stem cells.

Melanoma is one of the deadliest cancers, yet the cells of origin and mechanisms of tumor initiation have not been identified. More...
The majority of melanomas emerge from clear skin without a precursor lesion, but it is not known whether these melanomas can arise from melanocyte stem cells (MCSCs).

To clarify this point, investigators at Cornell University (Ithaca, NY, USA) employed mouse models to define the role of MCSCs as melanoma cells of origin. In particular, they evaluated the effect of the Hmga2 protein in MCSCs. This protein is encoded by the HMGA2 gene and belongs to the non-histone chromosomal high-mobility group (HMG) protein family. HMG proteins contain structural DNA-binding domains and may act as transcriptional regulating factors that function as architectural factors. The expression of HMGA2 in adult tissues is commonly associated with both malignant and benign tumor formation, as well as certain characteristic cancer-promoting mutations.

The investigators worked with mice carrying mutated MCSCs with intact HMGA2 and with another group in which HMGA2 had been deleted.

Results published in the October 12, 2017, online edition of the journal Cell Stem Cell revealed that Hmga2 (High-mobility group AT-hook 2) in the skin played a critical role in UVB-mediated melanoma formation and that abrogation of Hmga2 function in the microenvironment could suppress MCSC-originating cutaneous melanomas. The investigators concluded that melanomas originated from melanoma-competent MCSCs upon stimulation by UVB, which induced MCSC activation and translocation via an inflammation-dependent process.

“If you had mutations that were sufficient for melanoma, everything would be fine until you went out and got a sunburn,” said senior author Dr. Andrew White, assistant professor of biomedical sciences at Cornell University. “We have an actual mechanism, with Hmga2, that can be explored in the future and could be a way we can prevent melanomas from happening.”

Related Links:
Cornell University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.